Sheet	1 of 1		AUG 1 9 2002		Dr	#13
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY, DOCKET NO	D. COLT & TRAILEMAN	SERIAL NO.	TE	CEIV UG 2 1 200 ENTER 1600/
		3764-2 APPLICANT	4 :	09/508,195	A	UG 2 1 200
					TECH CA	ENTED :
		HARDERN et al		GROUP		-NIEH 1600/
		March 8, 2000		1624		
	ran Manak	U.S. PAT	ENT DOCUMENTS			
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	CLIDCL ACC	FILING DATE
INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPROPRIA
	7717.71					
		FOREIGN P	PATENT DOCUMENTS	3		TRANSLATIO
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES NO

	OTHER DOC	UMENTS (including	Author, Title, Date, I	Pertinent pages,	etc.)	
RIF	A. David Rodrigues; Co	ommentary, "Use of	In Vitro Human Metab	olism Studies in D		oment;
// / 	Biochemical Pharmaco Mistry, et al; "Glucuron				atic Coniug	ation of
	Morphine, Naloxone, a	nd Buprenorphine; ា	The American Society t			
	Therapeutics"; Vol. 15, J. Brian Houston; Com			m Data in Predictir	na In Vivo M	
	Clearance; Biochemica	al Pharmacology", V	ol. 47, No. 9, pp. 1469-	1479, 1994.		
	Martindale Thirty-third Awni, et al; "The Effect	edition; "The Complete of Mild or Moderate	ete Drug Reference"; F	Pharmaceutical Pro	ess; pp. 108	36-1089.
	Zileuton"; Clin. Pharac	okinet, 29 (Suppl. 2)	: 49-61, 1995.		namacokir	IEUCS OI
/		1				
	i i					
	nn.	1				

Form PTO-FB-A820 (Also PTO-1449)